Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab Journal Article

Authors: Morales, A. V.; Advani, R.; Horwitz, S. M.; Riaz, N.; Reddy, S.; Hoppe, R. T.; Kim, Y. H.
Article Title: Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab
Abstract: Background: Optimal treatment of indolent primary cutaneous B-cell lymphoma (CBCL), marginal zone lymphoma, and follicle center lymphoma, presenting as multiple lesions, has yet to be established. Rituximab is a chimeric monoclonal IgG1 antibody directed against the CD20 antigen of B cells. Clinical efficacy of systemic rituximab in CBCL has yet to be established. Objective: We sought to assess the efficacy of systemic rituximab in the treatment of CBCL. Methods: This was a retrospective study of 15 patients with indolent CBCL treated with intravenous rituximab (375 mg/m2) as a single agent. Variable maintenance regimen was used in a subset of patients. Responses were categorized as complete response, partial response, stable disease, or progressive disease. The efficacy end points included were objective response rate, time to response, time to progression, and duration of response. Results: Ten patients with follicle center lymphoma and 5 with marginal zone lymphoma were included. The objective response rate was 87% (60% complete response, 27% partial response). All patients with follicle center lymphoma had a response with 80% achieving complete response. Of the patients with marginal zone lymphoma, 3 had a response, one stable disease, and one progressive disease. Median follow-up was 36 months. Median time to response, duration of response, and time to progression was 30 days, 24 months, and 24 months, respectively. Limitations: The study was limited by the small sample size and retrospective design. Conclusions: This study, although small, suggests that rituximab is a reasonable first-line treatment option for indolent CBCL with multiple lesions where local treatment is not effective or desirable. © 2008 American Academy of Dermatology, Inc.
Keywords: adult; clinical article; treatment response; aged; middle aged; retrospective studies; drug efficacy; treatment duration; rituximab; follow up; skin neoplasms; b cell lymphoma; lymphoma, b-cell; antibodies, monoclonal; injections, intravenous; skin lymphoma
Journal Title: Journal of the American Academy of Dermatology
Volume: 59
Issue: 6
ISSN: 0190-9622
Publisher: Mosby Elsevier  
Date Published: 2008-12-01
Start Page: 953
End Page: 957
Language: English
DOI: 10.1016/j.jaad.2008.08.005
PUBMED: 18817999
PROVIDER: scopus
Notes: --- - "Cited By (since 1996): 8" - "Export Date: 17 November 2011" - "CODEN: JAADD" - "Source: Scopus"
Citation Impact
MSK Authors
  1. Steven M Horwitz
    482 Horwitz